T
Teresa R. Ward
Researcher at Merck & Co.
Publications - 5
Citations - 8881
Teresa R. Ward is an academic researcher from Merck & Co.. The author has contributed to research in topics: Gene & Genome. The author has an hindex of 4, co-authored 5 publications receiving 8426 citations.
Papers
More filters
Journal ArticleDOI
Functional profiling of the Saccharomyces cerevisiae genome.
Guri Giaever,Angela M. Chu,Li Ni,Carla Connelly,Linda Riles,Steeve Veronneau,Sally Dow,Ankuta Lucau-Danila,Keith Anderson,Bruno André,Adam P. Arkin,Anna Astromoff,Mohamed El Bakkoury,Rhonda Bangham,Rocío Benito,Sophie Brachat,Stefano Campanaro,Matt Curtiss,Karen Davis,Adam M. Deutschbauer,K. D. Entian,Patrick Flaherty,Françoise Foury,David J. Garfinkel,Mark Gerstein,Deanna Gotte,Ulrich Güldener,Johannes H. Hegemann,Svenja Hempel,Zelek S. Herman,Daniel F. Jaramillo,Diane E. Kelly,Steven L. Kelly,Peter Kötter,Darlene LaBonte,David C. Lamb,Ning Lan,Hong Liang,Hong Liao,Lucy Y. Liu,Chuanyun Luo,Marc Lussier,Rong Mao,Patrice Menard,Siew Loon Ooi,José L. Revuelta,Christopher J. Roberts,Matthias Rose,Petra Ross-Macdonald,Bart Scherens,Greg Schimmack,Brenda Shafer,Daniel D. Shoemaker,Sharon Sookhai-Mahadeo,Reginald Storms,Jeffrey N. Strathern,Giorgio Valle,Marleen Voet,Guido Volckaert,Ching Yun Wang,Teresa R. Ward,Julie Wilhelmy,Elizabeth A. Winzeler,Yonghong Yang,Grace Yen,Elaine M. Youngman,Kexin Yu,Howard Bussey,Jef D. Boeke,Michael Snyder,Peter Philippsen,Ronald W. Davis,Mark Johnston +72 more
TL;DR: It is shown that previously known and new genes are necessary for optimal growth under six well-studied conditions: high salt, sorbitol, galactose, pH 8, minimal medium and nystatin treatment, and less than 7% of genes that exhibit a significant increase in messenger RNA expression are also required for optimal Growth in four of the tested conditions.
Journal ArticleDOI
Functional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis
Elizabeth A. Winzeler,Daniel D. Shoemaker,Anna Astromoff,Hong Liang,Keith Anderson,Bruno André,Rhonda Bangham,Rocío Benito,Jef D. Boeke,Howard Bussey,Angela M. Chu,Carla Connelly,Karen Davis,Fred S. Dietrich,Sally Dow,Mohamed El Bakkoury,Françoise Foury,Stephen H. Friend,Erik Gentalen,Guri Giaever,Johannes H. Hegemann,Ted Jones,Michael T. Laub,Hong Liao,Nicole Liebundguth,David J. Lockhart,Anca Lucau-Danila,Marc Lussier,Nasiha M'Rabet,Patrice Menard,Michael Mittmann,Chai Pai,Corinne Rebischung,José L. Revuelta,Linda Riles,Christopher J. Roberts,Petra Ross-Macdonald,Bart Scherens,Michael Snyder,Sharon Sookhai-Mahadeo,Reginald Storms,Steeve Veronneau,Marleen Voet,Guido Volckaert,Teresa R. Ward,Robert W. Wysocki,Grace Yen,Kexin Yu,Katja Zimmermann,Peter Philippsen,Mark Johnston,Ronald W. Davis +51 more
TL;DR: A total of 6925 Saccharomyces cerevisiae strains were constructed, by a high-throughput strategy, each with a precise deletion of one of 2026 ORFs (more than one-third of the ORFs in the genome), finding that 17 percent were essential for viability in rich medium.
Journal ArticleDOI
Widespread aneuploidy revealed by DNA microarray expression profiling.
Timothy P. Hughes,Christopher J. Roberts,Hongyue Dai,Allan R. Jones,Michael R. Meyer,David J. Slade,Julja Burchard,Sally Dow,Teresa R. Ward,Matthew J. Kidd,Stephen H. Friend,Matthew J. Marton +11 more
TL;DR: The general usefulness of expression profiles for nearly 300 Saccharomyces cerevisiae deletion mutants, obtained recently, is demonstrated, with implications for interpreting whole-genome expression data, particularly from cells known to suffer genomic instability, such as malignant or immortalized cells.
Journal ArticleDOI
Chromosome 20q Amplification Regulates in Vitro Response to Kinesin-5 Inhibitor
Aimee L. Jackson,Mao Mao,Sumire Kobayashi,Teresa R. Ward,Matthew Biery,Hongyue Dai,Steven R. Bartz,Peter S. Linsley +7 more
TL;DR: The results suggest that patients whose tumors overexpress AurKA due to amplification of 20q will more likely resist treatment with Kinesin-5 inhibitor, and that inactivation of AURKA may sensitize these patients to treatment.
Patent
LXR-ligand induced genes and proteins
TL;DR: In this paper, the LXR-Ligand Induced I (LXRLI1) gene expression profile was used to diagnose a disease or disorder involving LXR activity, screen for compounds that change the activity of LXR and to classify LXR ligands.